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Contested futures: envisioning “Personalized,”
“Stratified,” and “Precision” medicine
Sonja Erikainen * and Sarah Chan
Usher Institute of Population Health Sciences and Informatics, College of Medicine and
Veterinary Medicine, University of Edinburgh, Edinburgh, UK
In recent years, discourses around “personalized,” “stratified,” and “precision”
medicine have proliferated. These concepts broadly refer to the translational
potential carried by new data-intensive biomedical research modes. Each
describes expectations about the future of medicine and healthcare that data-
intensive innovation promises to bring forth. The definitions and uses of the
concepts are, however, plural, contested and characterized by diverse ideas
about the kinds of futures that are desired and desirable. In this paper, we
unpack key disputes around the “personalized,” “stratified,” and “precision”
terms, and map the epistemic, political and economic contexts that structure
them as well as the different roles attributed to patients and citizens in
competing future imaginaries. We show the ethical and value baggage
embedded within the promises that are manufactured through terminological
choices and argue that the context and future-oriented nature of these choices
helps to understanding how data-intensive biomedical innovations are made
socially meaningful.
Keywords: personalized; stratified; precision; expectations
The last few decades have seen a proliferation of academic publications and policy
discourses around so-called “personalized,” “stratified,” or “precision” medicine.
While definitions of these terms are often debated, they all broadly refer to the pos-
sibilities that are opened up by the translation of emerging modes of data-intensive
biomedical research to the context of medical practice and healthcare delivery. This
is contextualized by the so-called “digital era” of bioinformatics and “big data”
which is enabling the collation of, and application of predictive modeling
methods to, unprecedented quantities of biomedical data. The rise of these technol-
ogies is associated with hopes and aspirations of a revolutionary change in medi-
cine that will enable new, transformed modes of healthcare delivery in the
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future. “Personalized,” “stratified,” and “precision” medicine each describe, in
different ways, the kinds of future medicine and healthcare that these new
methods promise to bring forth.
The concepts of “personalized,” “stratified,” and “precision” medicine and the
discourses associated with each are overlapping and future-oriented, characterized
by diverse visions of possible, desired and desirable futures that are illustrated by
the plurality of terms. These visions in turn are articulated in different ways in
different political and epistemic contexts, by different actors with different interests
and agendas. The meanings of “personalization,” “stratification,” and “precision”
are emergent, without collectively agreed boundaries: they refer to overlapping
phenomena and collate shared themes, but each has a different emphasis, which
delineates what is and is not included under each term in practice. Each reflects
different views of what the aims of emerging biomedical research modes are and
should be in the context of healthcare, and positions patients and citizens differently
with respect to health and biomedicine as well as in relation to governance and the
state.
Building on and contributing to existing literature on the sociology of expec-
tations, our objectives in this paper are, firstly, to delineate key aspects of the nego-
tiations and disputes attached to “personalized,” “stratified,” and “precision”
medicine, in order to analyze the divergent and overlapping themes that structure
the related discourses. We aim to unpack the various aspirations and epistemic
agendas attached to them, and to show how and why different terms are mobilized
in policy discourses as opposed to biomedical academic discourses. Second, we
map the political, and economic contexts that structure different policy articulations
of “personalized,” “stratified,” and “precision” medicine along the lines of US vs
Europe differences and similarities, as the articulations have largely originated
from and are advanced by US and European political actors. We show how poli-
tico-economic interests and cultural differences between the US and European
policy contexts frame how different future promises are imagined. Third, we aim
to show how the patients and citizen subjects that are the target of medical interven-
tions and healthcare systems are configured differently within and through the com-
peting discourses and imaginaries.
By providing insight into how (the concepts of) “personalized,” “stratified,” and
“precision” medicine are delineated and mobilized, we examine how the future-
oriented content of the discourses is likely to shape the direction of biomedical
innovation today. What aspirations do different politically, epistemically, and geo-
graphically positioned actors attach to new and emerging biomedical research
modes? What role do these aspirations play in envisioning the future of medicine
and healthcare? How are different visions of this future embedded within and
shaped by broader contexts in which they are articulated? How are individuals
and citizens being (re)positioned with respect to health, healthcare systems and bio-
medicine? Through charting this contested conceptual landscape, we explore how
the dispute over labels and definitions reflects political, social, epistemological and
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ontological tensions that must be negotiated as part of making sense of techno-
scientific and biomedical innovation. We argue that analysis of such innovation
and its implications must account, not just for this diversity of terms and the con-
textual differences that underlie it, but also for the ethical and value “baggage”
embedded with the future promises that are manufactured through terminological
choices.
Big data, systems biomedicine, and the sociology of expectations
The emergence of data-intensive biomedical methodologies and predictive ana-
lytics is contextualized by the “digital era” of scientific and technological inno-
vation that has exponentially increased computational processing power and
enabled the development of complex digital and interactive communication
systems and high-throughput technologies including genome sequencing and
-omics disciplines. Digital data collection, collation and analysis tools have
enabled new research modes that rely on “big data,” i.e. large quantities of
varied, dynamic, and mobilizable data (Kitchin 2014). New possibilities for con-
structing and collating datasets on an unprecedented scope and scale enable the
integration of myriad types of data ranging from electronic medical records to indi-
vidual and population genomics data to environmental sensor and lifestyle data
from personal mobile devises and applications (Lupton 2013). Some have
argued that big data even facilitates so-called “hypothesis free” research, based
on patters and correlations emerging from the data rather than on hypothesized
causal pathways (e.g. Baxter, Krokosky, and Terry 2011). Many emerging research
methods for making sense of big data have focused on the development of analysis
tools and algorithms that enable the integration of diverse data types to construct
predictive models of health and disease. While often based on the collation and
combined analysis of population data, this kind of predictive modeling tends to
be aimed at translating big health data into more targeted and focused – or person-
alized, stratified, or precise – medical and healthcare interventions for individual
subjects or groups (Flores et al. 2013).
These new technologies and methods have altered the focus of much biomedical
research, giving rise to an epistemic and ontological emphasis on “systems” or net-
works. This is rooted in the emergence of so-called systems biology, focused on the
dynamics of complex biological systems rather than individual parts or constituents
of the system. The application of systems approaches to medical and clinical con-
texts has been termed “systems medicine.” Both entail an ontological and epis-
temological re-direction in biomedicine (see Fujimura 2005; Green 2017; Powell
et al. 2007). They aim to move away from “object centered” approaches that
place emphasis on ontology, such as “molecular” or “cell” biology where the defi-
nition focuses on the object of study, or medical specializations around an object of
investigation, such as cardiology or oncology. Rather, emphasis is directed at
“systems” as a methodological and epistemological approach and on the
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construction of models of biological and disease pathways, which can enable a pre-
dictive rather than responsive approach to medicine. These emerging research
modes are interdisciplinary, requiring collaboration between researchers with
diverse backgrounds in biology and medicine, associated -omics disciplines, infor-
matics, computer sciences, statistics, mathematics, and even social sciences, all of
whom bring different epistemic frames reflecting their disciplinary training (Fagan
2017). Relatedly, others have shown how the interdisciplinary spaces of systems
biology and systems medicine are characterized by different ideas about what
the most significant aspects are that distinguish “systems” approaches from other
biomedical approaches, and about where research efforts should be directed (see
Green 2017).
Hence, the conceptual negotiations around “personalized,” “stratified,” and “pre-
cision”medicine on which this paper focuses are occurring against this background
of biotechnological innovation. The “personalized,” “stratified,” and “precision”
concepts are generally mobilized to describe the kinds of futures that data-intensive
and predictive or systems approaches could or should enable. Indeed, formidable
claims have been made about their potential to improve and re-direct medicine
and healthcare. Particularly provocative and vocal examples have been claims
made by Hood and colleagues (Flores et al. 2013; Hood and Friend 2011; Hood,
Balling, and Auffray 2012) who have prophesized that we are at the brink of a para-
digm shift; a medical revolution that will transform healthcare in the near future.
Hood and colleagues predict that in the next few years, each patient will be sur-
rounded by a virtual, longitudinal, multi-source and heterogeneous “data cloud”
which can be interpreted to predict risks of disease before onset, enabling medicine
to focus on optimizing health and wellness rather than on treating illness. This new
generation of medicine will be personalized by accounting for individuals’ unique
biological, environmental and lifestyle characteristics. Personalization will be
accompanied with a participatory system where patients and citizens contribute
their medical and health data to the benefit of research and are “empowered to
take responsibility” over their own health by keeping track of their health data
and modifying lifestyle in response to personalized preventative medical
information.
Hood and colleagues’ vision of “predictive, preventive, personalized and parti-
cipatory” medicine – what they call “P4 medicine” (Hood, Balling, and Auffray
2012) – is, however, only one example of a cluster of visions that have been articu-
lated in the last two decades. Several terms have emerged that aim to capture, in a
word, the new and transformed medicine that will soon be enabled, the most widely
used of which have been “personalized” medicine, followed by “stratified” and
“precision” medicine. For this reason, we focus on these three terms.
Existing theoretical and empirical contributions to the sociology of expectations
have demonstrated how new and emerging biotechnologies and techno-scientific
innovations are characterized by future-oriented expectations and visions that are
manufactured and attached to the technologies as their “promise” (e.g. Broer and
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Pickersgill 2015; Borup et al. 2006; Brown and Michael, 2010; Brown, Rappert,
and Webster 2000; Moirera and Palladino 2005). These expectations are “a way
of attracting and synthesizing different kinds of capital” (Broer and Pickersgill
2015, 48), including economic, but also social, cultural and symbolic capital (Bour-
dieu 1986), that help to enroll different actors in support of particular research
agendas and innovation models. The expectations and visions that articulate
them play a performative role in relation to new technologies: the future promises
that are manufactured by those visions that gain dominance in turn shape economic,
social, cultural and symbolic forms of investment that are directed at the realization
of particular kinds of futures (often at the expense of others) (Brown and Michael,
2010).
Moirera and Palladino (2005), among others, have argued that discourses around
biomedical innovation tend to deploy a rhetoric of “hope” whereby research and
scientific developments are justified by the promise of new treatments or “miracu-
lous” medical innovations. These hopes and promises can, in turn, be carried by
particular terms or labels via the connotations that they carry. Hedgecoe (2003),
for example, has shown how the term “pharmacogenomics” was mobilized as a
rhetorical device to gain support from policymakers and funders for research
topics grouped under the term, by tapping into the “hype” surrounding the word
“genomics.” Similarly, the terms “personalized,” “stratified,” and “precision”medi-
cine have been mobilized by key political and biomedical actors in contextual ways
that invoke particular associations and connotations. They have also been used in
ways that are embedded within and support politically and economically motivated
constructions of the “responsible citizen” subject, which draw from contextual
articulations of the duties and rights of individuals in relation to collectives, includ-
ing the state.
While the use and choice of the “personalized,” “stratified,” and “precision”
terms is significantly directed, especially in policy but also biomedical discourses,
by the expectations and promises of a better future, the choice and definition of the
terms are also shaped, especially in biomedical discourses, by what Moirera and
Palladino (2005) have called the deployment of “truth.” This entails “an investment
in what is positively known, rather than what could be” (Moirera and Palladino
2005, 67). In practice, this implies a kind of “epistemic modesty” (Will 2010) –
the deployment of what is “realistic” and what new biomedical technologies can
actually deliver, in opposition to, or as a warning against, (what are framed as
unrealistic) promises and hopes around “personalized,” “stratified,” and “pre-
cision” medicine. While both “hope” and “truth” function as rhetorical devices
that are used to make future-oriented claims in order to shape the present, different
expectations and articulations of possible futures are positioned differently in terms
of the epistemic status and value they are claimed, by different actors, to carry in the
marketplace of ideas.
We argue, then, that to understand the meaning and implications of “personal-
ized,” “stratified,” and “precision” medicine, we must look, not into the future,
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but at how the future as a temporal abstraction is constructed, managed, invested in,
by whom, and under what conditions (Brown, Rappert, and Webster 2000).
Personalized medicine
“Personalized medicine” has been the most common label applied in biomedical
discourses to describe the future potential and aims of translational big data, predic-
tive and systems biomedicine (Pokorska-Bocci et al. 2014). It has also become the
dominant term used in European policy discourses, having been adopted by the
European Commission as the preferred term to denote related emerging technol-
ogies and research in the context of European healthcare systems. There are,
however, two key sources of dispute around the meaning and scope of the
concept: first, whether or not “personalized medicine” is an appropriate term to
use; and second, what exactly the concept does or should encompass (De
Grandis and Halgunset 2016). Both disputes are related to the future-oriented
ways in which the concept is applied, and to the contextual ways in which its
meaning is interpreted and delineated by different policy and biomedical actors.
In the European policy context, EU funding programs have been investing in
“personalized medicine” since the 7th European research and technological devel-
opment framework program began in 2007. The current investment includes the
Horizon 2020 program and its Innovative Medicines Initiative, aimed at accelerat-
ing the development of effective preventative and diagnostic tools. Through these
programs alone, over 3 billion Euros of EU funding has been invested to support
research grouped under the label (Nimmesgern, Benediktsson, and Norstedt
2017). In 2015, the European Commission coined a definition of personalized
medicine according to which
personalised medicine refers to a medical model using characterisation of individuals’
phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data)
for tailoring the right therapeutic strategy for the right person at the right time, and/or
to determine the predisposition to disease and/or to deliver timely and targeted pre-
vention. Personalised medicine relates to the broader concept of patient-centred
care, which takes into account that, in general, healthcare systems need to better
respond to patient needs (Council of the European Union 2015).
This definition was applied by the Horizon 2020 program, which identified person-
alized medicine as a core theme, and highlighted better understanding of disease
etiology at a systems level as a key research priority (European Commission
2017). The Horizon advisory group justified the choice of “personalized medicine”
over alternative terms by noting that this “term best reflects the ultimate goal of
effectively tailoring treatment based on an individual’s ‘personal profile’, as deter-
mined by the individual’s genotype and phenotype data” (European Commission
2016a, 19).
The European Commission’s and associated organizations’ terminological and
definitional choice is explicitly connected with the aim and hope that the translation
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of systems approaches to healthcare will enable both a preventative model of medi-
cine and, relatedly, the incorporation of greater patient participation and account-
ability to the management of their own health. Illustrative is the Strategic
Research and Innovation Agenda (SRIA) developed by the EU-funded PerMed
project, and aimed at shaping Europe’s vision for personalized medicine. The
SRIA called for “a paradigm shift for all citizens, researchers and national health-
care systems,” underlining the importance of patient participation and responsibil-
ity in the ownership and control of personal health data (PerMed2020 2015, 2).
Similarly, the European Commission’s 2015Making Access to Personalized Medi-
cine a Reality for Patients conference, organized to address the integration of per-
sonalized medicine into EU healthcare systems, emphasized the need to develop a
patient-centered approach for “the benefit of all Europe’s patients, now and in the
future” (Luxembourg Ministry of Health and European Commission 2015). The
International Consortium for Personalized Medicine (IC PerMed) was initiated in
2016 to advance these aims, including 20 public and private non-profit health
research funding and policymaking organizations (European Commission 2016b).
The choice of the term “personalized medicine,” together with its associated
emphasis on patient-centered approaches, citizens’ responsibility and control
over their health through predictive healthcare models, brings to the fore the
future aspirations driving research investment in the European policy context.
The investment is shaped by hopes for tailored treatments in terms of providing
“the right therapeutic strategy for the right person at the right time,” intertwined
with the conceptualization of personalized medicine as a “paradigm shift” not
only for researchers but also for healthcare systems and citizens. The aim of
placing citizens “at the center of healthcare” incorporates a desire to enable not
only sharing and ownership but also responsibility towards one’s data and one’s
health. This “responsibilization” in relation to health implies “personalization” of
healthcare “in the sense that more responsibility for management of healthcare is
primarily laid on or taken by individuals or their carers rather than medical pro-
fessionals” (Nuffield Council of Bioethics 2010, 30).
In contrast to European policy discourses, in the biomedical literature, although
personalized medicine has been celebrated as the enabler of “individualizing
patient care across the continuum (from health to disease)… resulting in an unpre-
cedented customization of patient care” (Ginsburg andWillard 2009, 278–279), the
term has a wide scope and inconsistent application and has also incited derision.
Indeed, some have argued that the idea of “personalization,” at least as treatment
individualization, is in practice demonstrably fallacious (Nicholls et al. 2014).
There have been several attempts to clarify the meaning and scope of the concept.
Perhaps the most influential of these has been a definition proposed by Schleidgen
and colleagues (2013) based on a systematic literature review of biomedical journal
articles. We will discuss this definition in some depth, because both the definition
itself and the methods through which it was derived illustrate how the concept
has been delineated and negotiated in biomedical literature more generally.
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Schleidgen and colleagues argue that the vagueness of “personalized medicine”
has unduly complicated public discourses around the concept, and fear that some
stakeholders might use it to further their particular (especially economic)
agendas in morally unacceptable ways. They contend that a shared understanding
of the term is required to mitigate these problems, but also that adequate analytic
criteria should be used to construct the definition to avoid arbitrariness. Conse-
quently, they propose and apply several a priori analytic criteria against which defi-
nitions can be evaluated. Key amongst these is that an adequate definition of
personalized medicine cannot diverge from what medical technologies and knowl-
edge can actually deliver. They argue that definitions including such goals as
“improving tailoring of prevention and therapy” at an individual level are false,
due to the impossibility of realizing this goal in practice. Their approach exempli-
fies the deployment of “truth” (Moirera and Palladino 2005) as a strategic (future-
making) device in opposition to (what are framed as) too “hopeful” or unrealistic
promises that circulate in policy and political discourses, where the (especially
economic) agendas advanced are taken to be ethically partial.
Indeed, Schleidgen and colleagues state unequivocally that personalized medi-
cine “is not medicine with a special focus on the interests and preferences of the
individual patient” and it “is not related to the term patient-centered medicine,”
nor can patient-centered medicine be realized solely through personalized medicine
(11). That some (including the European Commission) have conflated personalized
and patient-centered medicine demonstrates, for Schleidgen and colleagues, that
stakeholders can misuse the conceptual ambiguity of the term by inflating it with
optimistic meanings according to their own agendas when, in reality, “tailoring
means no more than stratification” (10). Several biomedical commentators have
agreed: Abettan (2016, 426), for example, argues that “personalized” medicine
“is catchy but misleading” for similar reasons, while Honoré (2012, 497) has
remarked that given “all the complex processes that drugs undergo in the body,
determining the pharmacokinetics and pharmacodynamics in detail will never be
possible” and related new methods can thus only be described as stratified, not per-
sonalized dosing.
The definition proposed by Schleidgen and colleagues (2013, 10) is that person-
alized medicine “seeks to improve stratification and timing of health care by utiliz-
ing biological information and biomarkers on the level of molecular disease
pathways, genetics, proteomics as well as metabolomics.” Yet, rather than
serving as a resolution to personalized medicine’s conceptual ambiguity, this defi-
nition and the criteria based on which it was constructed can themselves be taken to
exemplify context-dependent interests and aspirations that have become attached to
“personalized medicine” in biomedical contexts. Despite their condemnation of the
possible co-optation of the concept by stakeholder interests, Schleidgen and col-
leagues themselves arrive at their definition building on biomedical literature
alone. They promote their own definition as adequate for public engagement and
communication, even though they acknowledge the widespread use of the
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concept in public as well as academic discourses. This seems either to rely on the
assumption that biomedical literature is unbiased rather than itself representing the
views of particular stakeholders (De Grandis and Halgunset 2016), or to be an
attempt to assert authority over the definition of “personalized medicine” (via
deploying “truth,” with the corresponding claim to know what the truth is). In
the latter case, biomedical scientists are framed as the stakeholders with the most
significant “expertise” or authority to define what “personalized medicine”
means and can mean, realistically. Yet, rather than protecting “personalized medi-
cine” from stakeholder bias, Schleidgen and colleagues effectively appoint one sta-
keholder group as the (only) legitimate delineator of what “personalized” medicine
can be, to the extent that other stakeholders’ conflicting interests, including patient-
centeredness, are classed as “misuse” of the concept. Indeed, Schleidgen and col-
leagues’ definition can be seen as privileging the biological and molecular
interpretation of “personalization” as group-level treatment stratification, to the
explicit and purposeful exclusion of patient-centered interpretations.
Simmons and colleagues (2012) have noted that personalized medicine often
comes to serve as a catch-all term used synonymously with genomic medicine,
with this equation having the effect of narrowly focusing attention on the application
of genomic and related technologies, while diverting attention from broader appli-
cations of personalization in health and biomedicine. This includes marginalizing
environmental and socioeconomic triggers of health and disease as aspects of per-
sonalization. By contrast, some scholars especially in the humanities and social
sciences have suggested that this narrow interpretation should be seen only as
one part of a broader notion of personalization. Cherny and colleagues (2014),
for example, have proposed the term “biologically personalized therapeutics” to
denote these aspects, arguing that biological aspects should not be equated with,
but seen as a part of, a more holistic conception of “personalized medicine” that
would focus on patient-centered care and view patients as “whole persons.”
Relatedly, Schleidgen and colleagues’ emphasis on what medicine can in prac-
tice deliver and their desire to disentangle personalized medicine from patient-cen-
tered care not only render the European Commission’s aspirations for personalized
medicine as misuse of the concept, but also side-line the future-oriented motiv-
ations that foreground these aspirations. By excluding patient-centered care and
more inclusive interpretations of personalization as unrelated to personalized medi-
cine, their definition tends to foreclose possible futures where the boundaries of
both “personalization” and “medicine” more comprehensively incorporate data
from “systems” beyond the traditional focus of medicine; namely, the environ-
mental and/or socio-economic. These broader notions of personalization and medi-
cine are in part what shape related research investment in the European policy
context, illustrating a disconnect between policy aspirations, and agendas advanced
by Schleidgen and colleagues’ and other biomedical commentators. The disconnect
derives from differently articulated priorities linked with different stakeholders’
agendas and values.
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It is also noteworthy that while existing research on patients’ and publics’ per-
ceptions of personalized medicine is limited, the research that does exist (Budin-
Ljøsne and Harris 2016; Gray et al. 2012; Heusser 2015; McFarland 2014)
suggests that patients and publics generally place little emphasis on biology-
based treatment individualization or genomics for “personalized medicine.”
Rather, they highlight aspects including patient empowerment, ability to participate
in medical decisions, better physician-patient relationships and being in contact
with one’s physician as key to personalization, thus understanding patient-centered
care as central to personalized medicine. In Heusser’s (2015, 78) words, their con-
ceptions “are more humanistic in nature:” personalized medicine for the “lay public
does not match the biological meaning attributed to the term” but “is automatically
associated with a more holistic concept of the ‘person.’” Patients as key stake-
holders are actively involved in negotiating and delineating the meaning of perso-
nalization in the context of their own lives, in ways connected with
responsibilization and increased individual accountability over health management.
While “personalized medicine” has been the most prominent term in biomedical
literature as well as being adopted by the European Commission among others,
some have argued that the term “stratified” should be used instead of “personal-
ized” to evade the kinds of “overly optimistic” associations relating to the “perso-
nalization” concept that Schleidgen and colleagues wished to avoid.
Stratified medicine
Some policy influencers and academic biomedical commentators have advocated
“stratified medicine” as a preferable term to “personalized medicine,” in ways
that mirror critiques of the latter expressed in biomedical literature. The World
Health Organization (WHO), for example, has argued that “stratification” more
accurately “reflects the realistic effects of medicines at population level, while
the term ‘personalized medicine’ reflects the possibly overambitious promise of
individualized unique drug targeting and development” (2013a, 180). Similarly,
the UK Academy of Medical Sciences (AMS) adopted the concept of “stratifica-
tion” instead of “personalization,” defining it as “the grouping of patients based
on risk of disease or response to therapy by using diagnostic tests or techniques”
(2013, 5).
Thus, while stratified medicine has also been used to denote visions of the future
of healthcare promised by data-driven predictive or systems biomedicine, these
visions have simultaneously been contrasted against the “misleading and segmen-
ted” nature of “personalization,” compared to which “stratification” has been taken
as a concept that “better captures the hopes and aspirations of this new branch of
medicine” (Chataway 2012, 732). “Stratification” can thus be seen as more “epis-
temically modest” and “truthful” conceptualization than the “hopeful” and promis-
sory framings of “personalization.” Yet, like “personalization,” what exactly the
“stratification” concept implies is contested, and how “stratified medicine”
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differs from “personalized medicine” is subject to disagreement. Some biomedical
commentators have drawn distinctions between the two as different approaches,
whereby stratified medicine amounts to “the definition of population subgroups
on the basis of estimates of their differences in disease susceptibility and prognosis,
or responses to treatment” while personalized medicine has been “used to describe
the explicit focus on individual patients” (Matthews et al. 2014, 16). Others,
however, have argued that stratified medicine is a “prelude” to personalized medi-
cine (Maglo 2012, 138), including the AMS (2013b) which (while currently prefer-
ring the “stratification” concept) argued that stratified medicine is “an approach to
therapy that forms a key step on the path towards personalized healthcare.” They
thus mirror the European Commission and other advocates of “personalized medi-
cine” in understanding personalization as the ultimate end goal to be pursued.
A 2015 joint forum meeting co-organized by the UK AMS, however, concluded
that the language of stratification was potentially problematic due to its exiting
associations with social divisions – especially stratification along ethnic and socio-
economic lines – which could render the concept misleading or problematic when
applied in public communication or engagement (AMS 2015). Indeed, based on
research with UK stakeholders, Innovate UK and Sciencewise reported that lay
representatives’ initial responses to the “stratified medicine” terminology were
negative (Farrow, Swinn, and Bua 2014). This was because, firstly, the term was
seen as inaccessible and, secondly, it evoked associations between genetic stratifi-
cation and social stratification along racial and other sociodemographic lines, and
incited concerns over the implications of this. Young people in particular associated
the idea of stratification into treatment groups with racial profiling. Innovate UK
and Sciencewise thus concluded that when it comes to public communication,
“stratified medicine might not be the right term for this task” (Farrow, Swinn,
and Bua 2014, 24). While they noted that members of the public had suggested
alternative terms including “personalized medicine,” such alternatives were also
criticized as potentially misleading in ways resembling broader critiques of the
“personalization” term, especially in relation to associations of treatment
approached being based on individual rather than group characteristics. Communi-
cation about medicine, they argued (in ways that recall the deployment of “truth” in
contrast to “hope” by Schleidgen and colleagues), should not raise hopes that
cannot be realized (Farrow, Swinn, and Bua 2014).
Similarly, based on interviews and ethnographic research with stakeholders in
the US, Juengst and colleagues (2016) argue that the term “stratified” has failed
to gain traction in the US context due to its associations with racial and income stra-
tification, genetic and healthcare discrimination, and social injustice. To avoid these
associations and related social and political concerns around the language of “popu-
lation stratification,” Juengst and colleagues argue that a term with more neutral, if
not positive, connotations was needed. The term that has become hegemonic in the
US is “precision medicine.”
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Precision medicine
In the context of US policy and biomedical discourses, Juengst and colleagues
(2016) argue that a wave of “rebranding” or rhetorical reform has taken place,
with opinion leaders abandoning the previously more widely used “personalized
medicine” term in favor of “precision medicine.” In their 2011 Towards Precision
Medicine report, the National Research Council (NRC) of the US National Acade-
mies encouraged “precision medicine” research, describing it as having the “ulti-
mate endpoint” of enabling “the selection of a subset of patients, with a common
biological basis of disease, who are most likely to benefit from a drug or other treat-
ment” (NRC 2011, 37). As a justification for their choice of term, the NRC (2011,
12) noted that in comparison with “personalized medicine,” “precision medicine” is
“less likely to be misinterpreted as meaning that each patient will be treated differ-
ently from every other patient.” Charles Sawyers, who co-chaired the NCR com-
mittee that produced the Towards Precision Medicine report, commented that
while the committee “spent a considerable amount of time on whether we were
talking about personalized medicine or precision medicine,” the choice of “pre-
cision” was motivated by their wish to “convey a more precise classification of
disease into subgroups that in the past have been lumped together because there
wasn’t a clear way to discriminate between them” (cited in Katsnelson 2013, 249).
The NRC’s promotion of “precision medicine” gave the term some purchase over
alternatives (especially) in the US context. In January 2015, US president Barak
Obama launched what came to be called the Precision Medicine Initiative (PMI),
investing $215 million to realize the initiative’s mission of enabling “a new era of
medicine through research, technology, and policies that empower patients,
researchers, and providers to work together toward development of individualized
care” (White House 2015a). While the NRC initially used the “precision” term to
indicate subgroup classification, under the PMI, precision medicine is given a
notably different definition, as “an approach to disease treatment and prevention
that seeks to maximize effectiveness by taking into account individual variability
in genes, environment and lifestyle,” through a “combined analysis of biological,
environmental, and behavioral factors that contribute to health and disease” (NIH
2015, 6). It is promoted as a “bold new research effort to revolutionize how we
improve health and treat disease” (NIH 2018).Mirroring the European Commission,
the FDA, which was awarded $10 million for the development of new regulatory
and evaluation approaches for the PMI, noted that the goal of precision medicine
“is to target the right treatments to the right patients at the right time” (FDA 2017).
At the center of the PMI is the so-called “All of Us” research program adminis-
tered by the National Institute of Health (NIH) with the aim of recruiting one
million volunteers to form a longitudinal cohort reflecting the demographic diver-
sity of the US population. They hope to build a databank large enough to facilitate
detection of “associations between genetic and environmental exposures and a
wide variety of health outcomes” to enable “the exploration of biological, clinical,
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social, and environmental determinants of health and disease” (NIH 2015, 6–7).
The objective is to collect and record biospecimens, physical measurements, elec-
tronic health records, participant-provided data collected through surveys, and even
mobile and digital health data from health, fitness and wellness devices and appli-
cations. The databank has a wide range of anticipated applications including quan-
titative estimates of disease risk, optimization of screening and prevention
strategies, and is intended to be widely accessible including to “citizen scientists”
and “engaged participants” (NIH 2015, 19–20). This reflected the Obama adminis-
tration’s stated goal of ensuring that citizens and/or customers have access to their
own health data so that “in addition to treating disease, we can empower individuals
and families to invest in and manage their health” (White House 2015b). In
Obama’s words, precision medicine “helps us create a genuine health care
system as opposed to just a disease care system,” allowing “each of us to have suf-
ficient information about our particular quirks… that we can make better life
decisions” (White House 2016).
Notably, there is significant overlap between the definitions and conceptualiz-
ations of “personalized medicine” applied in the European policy context, and
the definitions and conceptualizations of “precision medicine” applied within the
PMI. Indeed, in launching the PMI, Obama seems to have taken the two terms
quite synonymously: while opting for precision medicine, he noted that “in some
cases people call it personalized medicine” (White House 2015c). The PMI concep-
tualization of precision medicine significantly departs from that initially promoted
by the NCR. Its similarity to European policy discourses around personalized medi-
cine, however, highlights how different terms carrying different associations have
been chosen and used in different policy contexts, but promoted in similar ways to
describe the promise of big health data and predictive systems level analysis.
The choice of “precision medicine” in the US policy context reflects both cri-
tiques and undesirable connotations of alternative terms, and how they manifest
in the sociohistorical and socioeconomic context of the US. The “precision”
term avoids critiques of the term “personalized” by evading the latter’s hopeful
but possibly overambitious promise, while still enabling policymakers to apply
the rhetorical force of medicine “tailored to individuals’ lifestyles, genes, environ-
ment and preferences.” It avoids associations with social divisions aroused by “stra-
tified medicine,” while simultaneously reframing the group stratification and
medical profiling that predictive and systems approaches enact as ethically
neutral or even positive “precision.” The latter rhetorical quality is particularly
noteworthy in the context of American politics of race, with a long history of
both racial segregation built on scientific racism, and prominent and powerful
anti-racist politics and opposition in response to this segregation. Applied as an
umbrella term, it also enables the joining of genomics (and other -omics fields)
with other ethically complex and controversial research modes such as biobanking
and data mining of electronic health records under the language of “precision.” It
has associations with notions such as “precision equipment,” and even resonates
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with “military precision” and the appeal of phrases like “precision bombing” in
contemporary American culture (Juengst et al. 2016). However, like the European
Commission’s emphasis on citizens’ responsibility towards personal health data,
the PMI is intertwined with the aspiration of enabling individuals to invest in
and manage their own health – to “make better life decisions.” The initiative,
like the European Commission’s investment in “personalized medicine,” is con-
nected with health “responsibilization,” which brings with it a tension between citi-
zens’ empowerment rhetoric in relation to health and increased individual
accountability over health.
While “precision medicine” has not been as popular as “personalized medicine”
in biomedical literature (Pokorska-Bocci et al. 2014), the concept has likewise been
defined and applied by biomedical researchers and scholars across disciplines in
ways closely resembling the language used to define personalized medicine. This
includes definitions of precision medicine as “treatments targeted to the needs of
individual patients” (Jameson and Longo 2015, 2229) and healthcare “individually
tailored on the basis of a person’s genes, lifestyle and environment” (Hodson 2016,
S49). Some have described precision medicine as “patient-centered and multifa-
ceted extension of personalized medicine” (Matthews et al. 2014, 16). The
WHO (2013b, 7–8) on the other hand stated that whereas “the term ‘stratified medi-
cine’ reflects the realistic effect [of using myriad data to define individual disease
patterns] on patient/population-level, ‘precision medicine’ reflects the clinical con-
sequences — a better treatment.” In biomedical as well as policy discourses, the
respective meanings attributed to personalized and precision medicine are thus
also muddled in important ways.
Future promises, present values
The futures that are imagined for data-intensive, predictive and systems biomedi-
cine are multiple and embedded within broader contextual frames, but there are
also overlapping themes that cross from one future vision to another, yet manifest
somewhat differently in ways that reflect contextual variances and different
agendas. “Personalized,” “stratified,” or “precision” medicines are emergent
phenomena, where the process of their emergence is one of delineation, negotiation
and contestation in relation to the activities that they encompass and the roles they
(should) play in broader contexts of healthcare and biomedicine. The aims that are
stated, and those that are implicit, in each version of personalized, stratified or pre-
cision medicine that are articulated in policy and biomedical discourses reflect the
interests and aspirations of the articulators, which relate not only to what the future
should look like, but also to what matters in the present.
In the policy context, shared aspirations to increase individuals’ capability to
take control of their own health are centrally embedded in political discourses in
both the US and Europe. Such control is promoted as empowering and desirable,
highlighting patients’ and citizens’ agency and the value of increased health
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knowledge and capacity. However, these discourses also carry connotations of
“responsibilization” and its possible implications.1 Increasing individuals’
control over their own health also involves increasing individuals’ responsibility
for their health, which in turn easily translates into heightened expectations and
even obligations around maintaining and promoting personal health. Whereas
many (especially biomedical commentators) have celebrated the revolutionary
and transformative potential of predictive, big data, and systems approaches in
this regard, some bioethicists and scholars in the social sciences have expressed
concern over the possible implications of responsibilization as a form of increased
surveillance and medicalization. This carries implications for what the role of the
individual citizens in systems medicine is or should be, as citizens are (re)posi-
tioned as agentic and increasingly accountable actors in health management and
diseases prevention.
These concerns recall Beck’s (1992) argument that we are living in a “risk
society” where omnipresent risks, ranging from environmental risks to terrorism
to health risks, dominate public discourses in unprecedented ways, positioning
ignorance and lack of knowledge about these risks as a dangerous failure to antici-
pate and prepare for them. Disaster arises from not-knowing while knowing
enables mitigation and control, which in the context of healthcare is being
framed as accountability over risks of illness and disease mitigated through individ-
ual agency. Vogt, Hofmann, and Getz (2016), for example, have argued that the
aims of these new and emerging approaches to biomedicine, which include as a
central characteristic a focus on prediction and prevention, have the implication
of rendering health and illness actionable as well as controllable. As noted
above, biomedical commentators such as Hood and colleagues have seen action-
able health information as empowering because it enables individuals to track
and modify their lifestyle and health behaviors to prevent illness. Vogt,
Hofmann, and Getz, however, worry that the impact will be the medicalization
of “health and life itself” achieved through medical(ized) social- and self-surveil-
lance. This also evokes Foucault’s (1991) “panopticism” thesis: “biomedicine
would strengthen its grip on what it means to lead a healthy life, and even lifestyle,
living itself, would be grounded in a continuous, technologically based monitoring
of risk-factors” (Vogt, Hofmann, and Getz 2016, 320). This, in turn, can “lead to a
damaging labelling of aspects of life as medical and displace other valid goals,
values and ways of understanding and tackling life” (320). Thus, “at stake is no
less than a person’s own ability to state ‘I am well’without having to consult a com-
putational mirror image” (320, original emphasis). Indeed, some have taken this
further to advance dystopia-like prophecies centered on medical surveillance and
control penetrating into our every-day lives: the post-genomic era is “setting the
stage for a digital panopticon” which will result in “an emptying or obliteration
of life (dissolving individuality into pure data)” (Zwarts 2016, 69, 85).
The drive towards responsibilization has, however, contextual manifestations in
the present as well the envisioned ‘panopticized’ future. These are influenced by
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broader economic and political drivers around healthcare investment, but structured
by key differences between the US and European healthcare frameworks. Both
contexts have been shaped by economic downturn and reduced public spending
at the wake of the 2008 global financial crisis, which placed extra pressure on exist-
ing demands on governments internationally to produce efficiency savings includ-
ing from health resources (Rooshenas et al. 2015). The drive towards citizen
responsibilization and investment in the hope of predictive and preventative (per-
sonalized or precision) medicine are aligned with political motives to cut public
spending on healthcare generally, but the politics of individual responsibility
over health are particularly resonant in the context of American individual-centered
culture.
Healthcare in the US is already, and has long been, fully marketized as a private
expense, structured by an employment-based health insurance system. In European
countries, however, the public sector has largely been expected to bear the costs of
healthcare, and principles of entitlement to healthcare access for all (through
public/national healthcare systems like the UK National Health Service) are
strongly embedded in the cultural value system. European welfare model-based
public healthcare systems have been grounded on the assumption that risk of
unforeseen illness is approximately equally shared and should therefore be
pooled (Busby and Martin 2006). However, the translation of predictive and pre-
ventative personalized, stratified or precision medicine frameworks for healthcare
poses a challenge to assumptions of equity and shared risk and, arguably, carry
more disruptive implications for European systems than for the marketized US
system. Due to the differences between their underlying ethical principles, the nor-
mative implications for existing healthcare systems will vary in relation to ideas
around how and why the healthcare system itself should be provisioned and
what the role of individual citizens should be in relation to the state.
Yet, within policy discourses, both “precision” and “personalized” medicine
initiatives are also entangled with promises of a new model of citizens’ and
publics’ participation, envisioned as (inter)active and collaborative with healthcare
and research professionals, policymakers and regulatory bodies. These discourses
frame healthcare around a social contract model of benefits and obligations where
taking responsibility over one’s health is enticed in exchange for personalized or
precision (or stratified) healthcare (Davies et al. 2017). The connection between
citizenship and biomedical science in general and genomics in particular has
been analyzed by others (e.g. Busby and Martin 2006; Rose and Novas 2005; Saba-
tello and Appelbaum 2017), especially in relation to the human genome project and
emergence of national and group identities based on population genomics (e.g.
Benjamin 2009; Schwartz-Marin and Restrepo 2013; Schwartz-Marin and Silva-
Zolezzi 2010). In the context of the PMI, discourses around “precision” healthcare
are intertwined with citizenship discourses promoting shared national interests and
values by appealing, not only to the liberal individualistic ethos embedded in the
American value system, but also to a shared national identity – “All of Us,” as
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the core research program is labeled (see also Sabatello and Appelbaum 2017).
Although less influential, discourses around a shared (cross-)European identity
and related citizenship rhetoric are also advanced by the EU in ways that embed
the European Commission’s promotion of personalized medicine. Because a col-
lective identity or sense of belonging have been taken as necessary for effective
shared governance, a rhetoric of “European” identity and “European citizenship”
is embedded in the EU framework (Kantner 2006) which also shapes how personal
responsibility over health is interpreted in the context of “European” healthcare for
“citizens of the European Union.”
In sum, then, for policymakers both in Europe and the US, emphasis is placed on
increasing the effectiveness of healthcare through prevention, responsibilization
and, consequently, a diminished burden of care carried by state and public health
authorities. The rhetoric mobilized – emphasis on “personalization” and patient-
centered care by the European Commission versus individualization and “pre-
cision” in the US – reflects the need for public approval of policy initiatives and
investment. Language applied in policy discourses must reflect both policymakers’
hopes for what the policies can and should deliver, but also harness national and
regional public discourses and citizens’ hopes around what “better” or improved
healthcare could or should mean.
While the most persistent thematic around personalized, stratified, and precision
medicine is the future-oriented nature of related discourses not only in policy but
also biomedical contexts, biomedical commentators have been more invested in
articulating, in Moirera and Palladino’s (2005, 67) words, what is “positively
known” about the translational potential of new biomedical research modes. As
noted above, this deployment of “truth” in contrast (or at least in addition) to
“hope” presumes that those who articulate it know what the “truth” is, and it
also implies a kind of epistemic modesty, which is positioned differently in
terms of the epistemic status it is implied to carry. This is most strongly illustrated
by the rationales advanced by biomedical commentators for the use of the “strati-
fication” rather than “personalization” term as a more realistic concept that
accounts for what the new biotechnologies can actually or “truly” deliver. It is
also illustrated by the definition of “personalized medicine” advanced by Schleid-
gen and colleagues: by prioritizing biomedical scientists’ conceptualizations of
“personalization,” they position biomedical discourse as either untainted by the
kinds of economic biases that shape policy discourses, or, at least, as having
more authority (derived from “expertise”) to know and define what “personalized
medicine” can “really” mean.
Biomedical and academic articulations of “personalized,” “stratified,” and “pre-
cision”medicine also need to be contextualized, however, in relation to the broader
landscape of academic and clinical research where scientists compete for research
funding in ways constrained by the conditions of limited research and healthcare
investment. Proponents of “personalized,” “stratified,” and “precision” medicines,
both in Europe and the US, compete not only against each other but also against the
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claims and promises made by other research areas in the marketplace of ideas to
secure investment in their projects. Biomedical scientists’ efforts to define and
delineate “personalized,” “stratified,” and “precision” medicines can be seen as
efforts to construct a marketable identity (and agenda) for an emerging biomedical
research area, and as efforts to distinguish their epistemological and ontological
approach to this area from other competing approaches. They can simultaneously
be seen as efforts to delineate the “newness” of their approach from past research
modes to secure public and policy interest and investment. Choosing and defining a
term that is then claimed as the label that collates different new big data, predictive,
and systems approaches is a way of unifying a cluster of emerging biomedical
research practices and activities in an intelligible way (Powell et al. 2007). This
unification, achieved via the demarcation of an ontological and epistemological ter-
ritory through terminological and definitional work, simultaneously foregrounds
and is reinterpreted in policy contexts, positioned within national and regional pol-
itical and policy agendas, and (re)framed by and for patients and publics in relation
to their interests and needs.
The open and fluctuating boundaries of “personalized,” “stratified,” and “pre-
cision” medicine reflect, then, the context-dependent nature of biomedical and
techno-scientific innovation, and how they come and are made to matter for and
by different actors and groups in different ways. The chosen terms and their defi-
nitions, as labels and boundary delineations, mirror different interests, agendas, and
visions around big data integration, preventative and systems approaches to biome-
dicine, in ways that make the terms and definitions work as marketing tools
especially around research investment (Powell et al. 2007). Which term gains dom-
inance in which context is, on the other hand, likely to shape biomedical innovation
in the present in contextual ways: if we envision and invest in the “ultimate goal” of
“personalized” medicine as treatment individualization embedded within a patient-
centered healthcare model, for example, the direction of medical and healthcare
innovation will differ from one in which the future of biomedicine was envisioned
to be treatment stratification based on biomarkers and genetics. These delineations
are also connected with and shape how patients and citizens are positioned (and
position themselves) in relation to related discourses and what kinds of roles
they are envisioned (and envision themselves) to have. Different actors have differ-
ent ideas about what their position is, or should be, in relation to biomedical inno-
vation and its future; choices over preferred terms also reflect attempts to negotiate
this position at a personal or individual level.
The ongoing negotiations and contestations over the present meaning and
future implications of personalized, stratified, and precision medicine derive
from uncertainties around what new and emerging big data, predictive and
systems biomedicine actually imply in practice, and what they can and should
become. These open questions reflect how new biomedical technologies, inno-
vations and approaches are socially navigated, contested, and delineated in the
context of their emergence.
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Conclusion
In dispute when it comes to which term should be chosen to denote the potential of
new and emerging big data, predictive, and systems approaches to biomedicine are
the social ideals and values that the different terms carry as their associations:
which terminology and definitions gain dominance, where, and why is a result
of struggle over these ideals, values, and priorities. The terminological debates,
then, and the related epistemic and ontological tensions around where focus is
placed and how conceptual boundaries are drawn are a matter of struggle over
what a desirable and realizable future does and does not, and should and should
not look like. Each term taps into different interests and links to future imaginaries
that can then be used to gather support for and investment in emerging research
activities. The future visions that prevail or gain prominence in different contexts
ultimately reflect the power of, and investment in, the future visions and promise
that has been manufactured.
Our aim has been to map how the contextual conceptual, terminological and defi-
nitional boundary work and the future-oriented temporality that characterizes it are
a key aspect of how biomedical innovations are made meaningful. The diversity of
concepts that invoke “hopes” and “truths” about various biomedical and healthcare
futures that could or should materialize also shape whose interests will ultimately
be served by biomedical innovation. How and by whom these futures are manufac-
tured matters because the temporal and contextual nature of the discourses around
personalized, stratified, and precision medicine are central to how they are concep-
tualized and understood.
Existing analyses around the potential implications of big data, predictive, and
systems focus in biomedicine – such as analyses focused on responsibilization,
increased medicalization and surveillance that they can give rise to – are necessary
and valuable, as are analyses focused on delineating the possible meanings and
scope of “personalization,” “stratification,” and “precision.” However, rather
than pinpointing which of these terms is the “correct” one or delineating the
“true” meaning of each, to know how we should critically approach the concepts
we need an awareness of the discursive contexts in which they are mobilized.
This is because the context ultimately structures the social and ethical implications
that “personalization,” “stratification,” or “precision” will have for medicine and
healthcare systems, and for different stakeholders. As big health data, predictive
and systems-level analysis are, themselves, emergent phenomena, the terminology
applied in the discursive spaces around these new biotechnologies and approaches
cannot be abstracted from their context. Rather, when we apply the “personaliza-
tion,” “stratification,” and “precision” terms, we invoke particular associations,
connotations, “hopes” and “truths” that are part of pre-existing epistemologically
and ethically loaded discourses that reflect broader and weightier struggles over
what is a good future.
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